0001104659-24-041462.txt : 20240401 0001104659-24-041462.hdr.sgml : 20240401 20240401070046 ACCESSION NUMBER: 0001104659-24-041462 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240401 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240401 DATE AS OF CHANGE: 20240401 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Liquidia Corp CENTRAL INDEX KEY: 0001819576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 851710962 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39724 FILM NUMBER: 24805501 BUSINESS ADDRESS: STREET 1: 419 DAVIS DRIVE, SUITE 100 CITY: MORRISVILLE STATE: NC ZIP: 27560 BUSINESS PHONE: 919.328.4400 MAIL ADDRESS: STREET 1: 419 DAVIS DRIVE, SUITE 100 CITY: MORRISVILLE STATE: NC ZIP: 27560 8-K 1 tm2410292d1_8k.htm FORM 8-K
false 0001819576 0001819576 2024-04-01 2024-04-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 1, 2024

 

LIQUIDIA CORPORATION
(Exact name of registrant as specified in its charter)
     
Delaware 001-39724 85-1710962

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

     
419 Davis Drive, Suite 100, Morrisville, North Carolina 27560
(Address of principal executive offices) (Zip Code)

  

Registrant’s telephone number, including area code: (919) 328-4400

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock LQDA The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 8.01 Other Events.

 

As previously disclosed, in December 2023, Liquidia Corporation, a Delaware Corporation (the “Company”), filed a request for Judge Andrews of the U.S. District Court for the District of Delaware (the “Delaware District Court”) to set aside the injunction that was instituted in August 2022 tied to litigation filed by United Therapeutics Corporation (“United Therapeutics”) alleging patent infringement of U.S. Patent No. 10,716,793 in Case No. 1:20-cv-00755-RGA (the “Original Hatch-Waxman Litigation”). On April 1, 2024, the Company issued a press release announcing that, on March 28, 2024, Judge Andrews set aside the injunction issued in the Original Hatch-Waxman Litigation. As a result, the U.S. Food and Drug Administration (the “FDA”) is no longer enjoined from issuing final approval of the Company’s New Drug Application (“NDA”) for YUTREPIA (treprostinil) inhalation powder (“YUTREPIA”). United Therapeutics has filed a notice of appeal with respect to Judge Andrews’ decision to set aside the injunction.

 

In addition, United Therapeutics has filed two separate lawsuits in which it is seeking to obtain new injunctions to prevent the launch of YUTREPIA for the treatment of pulmonary hypertension associated with interstitial lung disease (“PH-ILD”).

 

In the first action, United Therapeutics filed a lawsuit against the FDA in the U.S. District Court for the District of Columbia (the “D.C. District Court”) (Case No. 24-484), and a motion for a temporary restraining order and preliminary injunction, seeking to prevent the FDA from granting effective approval to the Company’s amended NDA from July 2023 which added the indication to treat PH-ILD. After a hearing was held on March 29, 2024, Judge Bates, who is presiding over this lawsuit in the D.C. District Court, denied United Therapeutics’ motion. The D.C. District Court has scheduled a status conference for April 2, 2024, to establish a process for United Therapeutics’ claims to be reevaluated after the FDA acts on the Company’s amended NDA.

 

In the second action, United Therapeutics filed a lawsuit against the Company in Delaware District Court (Case No. 23-975) alleging that YUTREPIA would infringe U.S. Patent No. 11,826,327, which was issued in November 2023. United Therapeutics has filed a motion for a preliminary injunction to block the Company from launching YUTREPIA for PH-ILD. Briefing on United Therapeutics’ motion remains in process.

 

A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated by reference into this Item 8.01.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
No.		   Exhibit
99.1   Press Release of Liquidia Corporation, dated April 1, 2024.
104   Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

April 1, 2024 Liquidia Corporation
   
  By: /s/ Michael Kaseta
    Name: Michael Kaseta
    Title: Chief Financial Officer and Chief Operating Officer

 

 

 

 EX-99.1 2 tm2410292d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder

 

·On March 28, Judge Andrews removed the injunction issued in the Original Hatch Waxman Litigation

 

·On March 29, Judge Bates denied United Therapeutics’ motion for temporary restraining order and preliminary injunction in separate litigation filed by United Therapeutics against the FDA

 

·On March 31, regulatory exclusivity expired for Tyvaso® in treating PH-ILD

 

MORRISVILLE, N.C., April 1, 2024 – Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that on March 28, Judge Andrews of the U.S. District Court for the District of Delaware (District Court) has set aside the injunction that was issued in August 2022 in the lawsuit filed by United Therapeutics (UTHR) in Case No. 1:20-cv-00755-RGA (the Original Hatch-Waxman Litigation). As a result, the U.S. Food and Drug Administration (FDA) is no longer enjoined from issuing final approval of Liquidia’s New Drug Application (NDA) for YUTREPIA™ (treprostinil) inhalation powder.

 

Dr. Roger Jeffs, Chief Executive Officer of Liquidia, said: “With the recent decision by Judge Andrews, the path is cleared for us to seek final approval for YUTREPIA. We have submitted the judge’s order to the FDA and look forward to a decision from the FDA in the near future. Our commercial team is fully prepared to launch YUTREPIA in both PAH and PH-ILD should the FDA grant final approval. Once launched, we are confident that YUTREPIA’s convenient, low-effort delivery and wide dosing range will propel the therapy towards our goal of establishing YUTREPIA as the prostacyclin of first choice.”

 

The FDA tentatively approved YUTREPIA to treat pulmonary arterial hypertension (PAH) in November 2021. In July 2023, the Company amended its NDA to add the indication to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). On March 31, 2024, the new clinical investigation exclusivity granted to Tyvaso® to treat PH-ILD expired. The FDA is now able to take final action on YUTREPIA’s amended NDA that seeks approval for both indications.

 

United Therapeutics has filed a notice of appeal with respect to Judge Andrews’ decision to set aside the injunction. In addition, United Therapeutics has filed two separate lawsuits in which it is seeking to obtain new injunctions to prevent launch of YUTREPIA for the treatment of PH-ILD. For both of these actions, UTHR bears the burden of demonstrating, among other things, that it is substantially likely to succeed on the merits and that UTHR will be irreparably harmed if the injunctions are not granted. None of these appeals or actions will impede the Company’s launch of YUTREPIA unless UTHR is successful in obtaining the relief it is seeking.

 

In the first action, UTHR filed a lawsuit against FDA in the U.S. District Court for the District of Columbia (Case No. 24-484), and a motion for a temporary restraining order and preliminary injunction, seeking to prevent FDA from approving Liquidia’s amended NDA. After a hearing on March 29, Judge Bates, who is presiding over this lawsuit, denied UTHR’s motion. Specifically, the Court held that the subject of UTHR’s case, FDA’s acceptance of Liquidia’s amended NDA for substantive review, is not a final agency action that UTHR can challenge in court. The Court has scheduled a status conference for April 2 to establish a process for UTHR’s claims to be reevaluated after the FDA acts on the Company’s amended NDA.

 

 

 

 

In the second action, UTHR filed a lawsuit against the Company in Delaware District Court (Case No. 23-975) alleging that YUTREPIA would infringe U.S. Patent No. 11,826,327 (‘327 patent), which issued in November 2023. UTHR has filed a motion for preliminary injunction to block Liquidia from launching YUTREPIA for PH-ILD. Briefing on UTHR’s motion remains in process.

 

About YUTREPIA™(treprostinil) inhalation powder

 

YUTREPIA is an investigational, inhaled dry powder formulation of treprostinil delivered through a convenient, low-effort, palm-sized device. The FDA previously issued tentative approval of YUTREPIA for the PAH indication in November 2021. YUTREPIA was designed using Liquidia’s PRINT® technology, which enables the development of drug particles that are precise and uniform in size, shape, and composition, and that are engineered for enhanced deposition in the lung following oral inhalation. Liquidia has completed INSPIRE, or Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil, an open-label, multi-center phase 3 clinical study of YUTREPIA in patients diagnosed with PAH who are naïve to inhaled treprostinil or who are transitioning from Tyvaso® (nebulized treprostinil). YUTREPIA is currently being studied in the ASCENT trial, an Open-Label Prospective Multicenter Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in Pulmonary Hypertension, with the objective of informing YUTREPIA’s dosing and tolerability profile in patients with PH-ILD. YUTREPIA was previously referred to as LIQ861 in investigational studies.

 

About Liquidia Corporation

 

Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The Company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. (Liquidia Technologies) and Liquidia PAH, LLC (Liquidia PAH). Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of PAH and PH-ILD. Liquidia Technologies is also developing L606, an investigational liposomal formulation of treprostinil administered twice-daily with a short-duration next-generation nebulizer, for use in North America. Liquidia PAH provides for the commercialization of pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection. For more information, please visit www.liquidia.com.

 

Tyvaso® is a registered trademark of United Therapeutics.

 

 

 

 

Cautionary Statements Regarding Forward-Looking Statements

 

This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding our future results of operations and financial position, our strategic and financial initiatives, our business strategy and plans and our objectives for future operations, are forward-looking statements. Such forward-looking statements, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs), regulatory applications and related submission contents and timelines, including the potential for final FDA approval of the NDA for YUTREPIA, the timeline or outcome related to patent litigation in the U.S. District Court for the District of Delaware, inter partes review proceedings conducted at the PTAB or other litigation instituted by United Therapeutics or others, including rehearings or appeals of decisions in any such proceedings, the issuance of patents by the USPTO and our ability to execute on our strategic or financial initiatives, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. The favorable decisions of courts or other tribunals are not determinative of the outcome of the appeals or rehearings of the decisions. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks discussed in our filings with the SEC, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Company Contacts

 

Investors:
Jason Adair
Chief Business Officer

919.328.4400
jason.adair@liquidia.com

 

Media Inquiries:

media@liquidia.com

 

 

 

 EX-101.SCH 3 lqda-20240401.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 lqda-20240401_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 lqda-20240401_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Cover
Apr. 01, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 01, 2024
Entity File Number 001-39724
Entity Registrant Name LIQUIDIA CORPORATION
Entity Central Index Key 0001819576
Entity Tax Identification Number 85-1710962
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 419 Davis Drive
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Morrisville
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27560
City Area Code 919
Local Phone Number 328-4400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock
Trading Symbol LQDA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://liquidia.com/role/Cover Cover Cover 1 false false All Reports Book All Reports lqda-20240401.xsd lqda-20240401_lab.xml lqda-20240401_pre.xml tm2410292d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2410292d1_8k.htm": { "nsprefix": "lqda", "nsuri": "http://liquidia.com/20240401", "dts": { "schema": { "local": [ "lqda-20240401.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "lqda-20240401_lab.xml" ] }, "presentationLink": { "local": [ "lqda-20240401_pre.xml" ] }, "inline": { "local": [ "tm2410292d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://liquidia.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-04-01", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2410292d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-04-01", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2410292d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-24-041462-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-041462-xbrl.zip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end XML 17 tm2410292d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001819576 2024-04-01 2024-04-01 iso4217:USD shares iso4217:USD shares false 0001819576 8-K 2024-04-01 LIQUIDIA CORPORATION DE 001-39724 85-1710962 419 Davis Drive Suite 100 Morrisville NC 27560 919 328-4400 false false false false Common stock LQDA NASDAQ false